The Apogenix management board combines entrepreneurial experience with a strong track record in pharmaceutical research and clinical development.

Dr. Thomas Hoeger
Chief Executive Officer

Thomas Hoeger, Ph.D., has been Chief Executive Officer of Apogenix since November 2005. Previously, he worked as a biotech analyst for DZ Bank in Frankfurt, Germany, for five years. From 1997 to 2000, he headed the 'Central Nervous System' research at BASF AG and Knoll AG. During the previous six years, he held various research and management positions at BASF AG.

Following his studies in biology at the Universities of Kiel and Heidelberg in Germany, and as Fulbright Scholar at the Massachusetts Institute of Technology (MIT) in Cambridge, MA, USA, Dr. Hoeger obtained his Ph.D. in 1991 for the doctoral work performed at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. In 2001, he completed his training as Certified European Financial Analyst (CEFA).

Phone:   +49 (0)6221 586080
E-Mail:    This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

 

Dr. Harald Fricke
Chief Medical Officer

Harald Fricke, M.D., has been Chief Medical Officer of Apogenix since January 2006. Previously, he was responsible for the global clinical development at Fresenius Biotech GmbH and headed Baxter Oncology's clinical development department for three years. From 1996 to 2001, he held various national and international management positions at SmithKline Beecham and GlaxoSmithKline, respectively.

Dr. Fricke obtained his M.D. in 1987 after studying medicine at the University of Aachen and the University of Luebeck in Germany. From 1987 to 1990, he worked as a postdoc at the Weizmann Institute of Science in Israel. Following his accreditation as a specialist in internal medicine in 1993, he received his habilitation in 1996 from Ludwig Maximilians University in Munich, Germany.

Phone:   +49 (0)6221 586080
E-Mail:    This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 
 
 

Peter Willinger
Chief Financial Officer

Peter Willinger is Chief Financial Officer of Apogenix. Before joining Apogenix, he was CFO of LION bioscience AG/SYGNIS Pharma AG in Heidelberg, Germany, where he oversaw the finance, investor relations, and corporate development departments. From 1998 to 2004, he was Director Controlling und Vice President Global Finance & Operations at LION bioscience AG. 

Following his studies in business administration at the Baden-Wuerttemberg Cooperative State University Mannheim, Willinger worked as a controller with Rudolf Wild GmbH in Heidelberg, Germany, for eight years before joining the finance department of LION bioscience AG.

Phone:   +49 (0)6221 586080
E-Mail:    This email address is being protected from spambots. You need JavaScript enabled to view it.